Aurorakinase
Aurora-Kinase-Inhibitoren zielen auf die Aurora-Kinasen ab, eine Familie von Serin/Threonin-Kinasen, die eine entscheidende Rolle bei der Regulierung der Mitose spielen. Diese Kinasen sind für die korrekte Chromosomenausrichtung, -segregation und Zytokinese während der Zellteilung unerlässlich. Abnorme Aurora-Kinase-Aktivität kann zu unkontrollierter Zellproliferation und Krebs führen. Durch die Hemmung von Aurora-Kinasen können diese Verbindungen einen Zellzyklusarrest und Apoptose in Krebszellen induzieren, was sie zu wertvollen Werkzeugen in der Krebsforschung und -therapie macht. Bei CymitQuimica bieten wir eine breite Palette hochwertiger Aurora-Kinase-Inhibitoren zur Unterstützung Ihrer Forschung in den Bereichen Zellzyklusregulation, Mitose und Onkologie an.
114 Produkte aus dem Bereich "Aurorakinase" gefunden
Sortieren nach
Reinheit (%)
0
100
|
0
|
50
|
90
|
95
|
100
Centrinone
CAS:Centrinone (LCR-263) (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM).Formel:C26H25F2N7O6S2Reinheit:98.76%Farbe und Form:SolidMolekulargewicht:633.65dAURK-4 hydrochloride
dAURK-4 hydrochloride, a derivative of Alisertib, functions as a potent and selective degrader of AURKA (Aurora A), exhibiting anticancer properties [1].Formel:C52H53Cl2FN8O12Reinheit:99.44%Farbe und Form:SolidMolekulargewicht:1071.93NU6140
CAS:NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 μM).Formel:C23H30N6O2Reinheit:98.33%Farbe und Form:SolidMolekulargewicht:422.52Ref: TM-T16359
2mg39,00€5mg60,00€10mg92,00€25mg177,00€50mg285,00€100mg414,00€200mg580,00€1mL*10mM (DMSO)67,00€Tinengotinib
CAS:Tinengotinib is a multikinase inhibitor that targets a series of kinases , including Aurora kinases A/B, JAK1/2, FGFR1/2/3, VEGFRs, and many other kinases.Formel:C20H19ClN6OReinheit:99.05%Farbe und Form:SolidMolekulargewicht:394.86TAK-901
CAS:TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among othersFormel:C28H32N4O3SReinheit:99.02% - 99.59%Farbe und Form:SolidMolekulargewicht:504.64Ref: TM-T2709
1mg35,00€5mg70,00€10mg104,00€25mg202,00€50mg329,00€100mg525,00€200mg748,00€1mL*10mM (DMSO)79,00€Aurora-A ligand 1
CAS:Aurora-A ligand 1 is a potent and selective inhibitor of Aurora-A, exhibiting a dissociation constant (Kd) of 0.85 nM. It serves as a target protein ligand [PROTAC target protein ligand] in the development of PROTAC Aurora-A degraders with antitumor activity. Additionally, Aurora-A ligand 1 is utilized in the synthesis of HLB-0532259, which exhibits antitumor effects against neuroblastoma.Formel:C21H23N5O3Farbe und Form:SolidMolekulargewicht:393.439GSK-1070916
CAS:GSK-1070916 (GSK-1070916A) is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM.Formel:C30H33N7OReinheit:99.73%Farbe und Form:SolidMolekulargewicht:507.63CD532 hydrochloride
CD532 hydrochloride, potent Aurora A inhibitor (IC50=45 nM), hampers MYCN protein, changes AURKA's shape, aids cancer research.Farbe und Form:SoliddAurAB2
dAurAB2 is a bifunctional PROTAC capable of effectively degrading Aurora-A and Aurora-B, with DC50 values of 59 nM and 39 nM, respectively. It reduces N-Myc levels in MYCN-amplified IMR32 neuroblastoma cells and is valuable for neuroblastoma research.Farbe und Form:Odour SolidPROTAC MPS1 degrader 1
PROTAC MPS1 degrader 1 (Compound 19) acts as a potent degrader of Monopolar spindle 1 (Mps1, TTK), AURKA, and AURKB, with DC50 values of 17.7, 108.7, and 570.3 nM respectively. It is utilized in the study of acute myeloid leukemia. (Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligase)Formel:C41H46N12O7Farbe und Form:SolidMolekulargewicht:818.88SK2187
CAS:SK2187 is a selective degrader of AURKAPROTAC with a DC50 of approximately 10 nM. It exhibits growth-inhibitory effects on NGP cells, with an IC50 value of 101.5 nM. SK2187 is utilized in studies of MYCN-amplified neuroblastoma.Formel:C45H49ClFN7O11SFarbe und Form:SolidMolekulargewicht:950.43Barasertib
CAS:AZD1152 is a pro-drug of Barasertib (AZD1152)-hQPA. Which is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay.Formel:C26H31FN7O6PReinheit:99.92% - 99.97%Farbe und Form:SolidMolekulargewicht:587.54CAM2602
CAM2602 is an inhibitor of Aurora A-TPX2 interaction, demonstrating a binding affinity of 19 nM with Aurora A. This compound has been shown to inhibit the growth of pancreatic cancer cells. In solid tumor xenograft models, CAM2602 increases the proportion of PH3-positive cells while decreasing the ratio of P-Thr288Aurora A-positive cells, ultimately inhibiting tumor growth.Farbe und Form:Odour SolidHLB-0532259
CAS:HLB-0532259 is a PROTAC degrader that targets the degradation of Aurora-A and N-Myc. In non-MYCN amplified MCF-7 cells, it degrades Aurora-A with a DC50 of 20.2 nM, and in MYCN amplified SK-N-BE and Kelly cells, it degrades N-Myc with DC50 values of 179 nM and 229 nM, respectively. HLB-0532259 has demonstrated antitumor activity in mouse models. (Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligaseCereblon)Formel:C40H44N8O7Farbe und Form:SolidMolekulargewicht:748.827Retreversine
CAS:Retreversine serves as an inactive control counterpart to Reversine, a pioneering class of ATP-competitive Aurora kinase inhibitor.Formel:C21H27N7OFarbe und Form:SolidMolekulargewicht:393.49AURKA against 1
Compound Ac13, also termed AURKA against 1, acts as an inhibitor of the Aurora kinase (AURKA) with an IC50 of less than 0.5 nM, targeting the acetylation of endogenous lysine (K162) and exhibiting anti-tumor cell proliferation activity. The kinase activity of AURKA, acetylated at K162 and induced by AURKA against 1, is reversibly restored in HCT116 cells transfected with SIRT3.Formel:C28H32FN9O2Farbe und Form:SolidMolekulargewicht:545.61TAS-119
CAS:TAS-119 (TAS-2104) is an orally available, selective and potent inhibitor of Aurora A with an IC50 of 1.0 nM.TAS-119 also inhibits Aurora B with an IC50 of 95Formel:C23H22Cl2FN5O3Reinheit:99.65%Farbe und Form:SolidMolekulargewicht:506.36Ref: TM-T34787
1mg97,00€5mg235,00€10mg378,00€25mg748,00€50mg1.169,00€100mg1.644,00€1mL*10mM (DMSO)261,00€JB300
CAS:JB300 is a PROTAC-based compound that serves as a highly selective degrader of Aurora A, with a DC50 of 30 nM. It is utilized in cancer research. JB300 comprises the PROTAC target protein ligand MK-5108 [pink part], E3 ligase ligand Thalidomide-O-COOH [blue part], and PROTAC Linker Boc-NH-PEG2-C2-NH2 [black part]. The conjugate of the E3 ubiquitin ligase ligand and linker is Thalidomide-O-COOH-NH2-C2-PEG2-NH-Boc.Formel:C43H45ClFN7O10SFarbe und Form:SolidMolekulargewicht:906.375SP-96
CAS:SP-96: Aurora B inhibitor, IC50=0.316 nM, selectively hinders MDA-MD-468 growth, GI50=107 nM, for triple-negative breast cancer research.
Formel:C25H20FN7OReinheit:99.54%Farbe und Form:SolidMolekulargewicht:453.47dAURK-4
CAS:dAURK-4, a derivative of Alisertib, functions as a potent and selective degrader of AURKA (Aurora A), exhibiting anticancer properties [1].Formel:C52H52ClFN8O12Farbe und Form:SolidMolekulargewicht:1035.47
